- Home
- ARAY vs PBYI Comparison
ARAY vs PBYI Comparison
Compare ARAY & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARAY
- PBYI
- Stock Information
- Founded
- ARAY 1990
- PBYI 2010
- Country
- ARAY United States
- PBYI United States
- Employees
- ARAY N/A
- PBYI N/A
- Industry
- ARAY Medical/Dental Instruments
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- ARAY Health Care
- PBYI Health Care
- Exchange
- ARAY Nasdaq
- PBYI Nasdaq
- Market Cap
- ARAY 170.1M
- PBYI 171.7M
- IPO Year
- ARAY 2007
- PBYI N/A
- Fundamental
- Price
- ARAY $1.57
- PBYI $4.47
- Analyst Decision
- ARAY Strong Buy
- PBYI Strong Buy
- Analyst Count
- ARAY 1
- PBYI 1
- Target Price
- ARAY $5.00
- PBYI $7.00
- AVG Volume (30 Days)
- ARAY 742.6K
- PBYI 679.9K
- Earning Date
- ARAY 11-05-2025
- PBYI 11-06-2025
- Dividend Yield
- ARAY N/A
- PBYI N/A
- EPS Growth
- ARAY N/A
- PBYI 434.29
- EPS
- ARAY N/A
- PBYI 0.97
- Revenue
- ARAY $458,505,000.00
- PBYI $238,062,000.00
- Revenue This Year
- ARAY $5.84
- PBYI N/A
- Revenue Next Year
- ARAY $3.90
- PBYI N/A
- P/E Ratio
- ARAY N/A
- PBYI $4.60
- Revenue Growth
- ARAY 2.68
- PBYI 8.63
- 52 Week Low
- ARAY $1.14
- PBYI $2.32
- 52 Week High
- ARAY $2.95
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- ARAY 56.74
- PBYI 45.38
- Support Level
- ARAY $1.54
- PBYI $4.49
- Resistance Level
- ARAY $1.64
- PBYI $5.22
- Average True Range (ATR)
- ARAY 0.06
- PBYI 0.28
- MACD
- ARAY -0.00
- PBYI -0.13
- Stochastic Oscillator
- ARAY 57.89
- PBYI 5.83
About ARAY Accuray Incorporated
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.